AR113440A1 - Tratamiento de glomeruloesclerosis focal y segmentaria con antagonistas de ccr2 - Google Patents

Tratamiento de glomeruloesclerosis focal y segmentaria con antagonistas de ccr2

Info

Publication number
AR113440A1
AR113440A1 ARP180102940A ARP180102940A AR113440A1 AR 113440 A1 AR113440 A1 AR 113440A1 AR P180102940 A ARP180102940 A AR P180102940A AR P180102940 A ARP180102940 A AR P180102940A AR 113440 A1 AR113440 A1 AR 113440A1
Authority
AR
Argentina
Prior art keywords
glomerulosclerosis
segmentary
focal
treatment
ccr2 antagonist
Prior art date
Application number
ARP180102940A
Other languages
English (en)
Inventor
Zhenhua Miao
Thomas J Schall
Rajinder Singh
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AR113440A1 publication Critical patent/AR113440A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)

Abstract

En la presente se proveen métodos para tratar glomeruloesclerosis focal y segmentaria, en donde dichos métodos incluyen administrar a un sujeto que lo necesita una cantidad terapéuticamente efectiva de un antagonista de CCR2. En algunas formas de realización, el antagonista de CCR2 se usa en monoterapia. En algunas formas de realización, el antagonista de CCR2 se usa en terapia de combinación. En algunas formas de realización, el agente terapéutico adicional es un bloqueador de RAAS y/o un inhibidor del receptor de la endotelina. Reivindicación 1: Un método de tratamiento de la glomeruloesclerosis focal y segmentaria, que comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente efectiva de un antagonista de CCR2.
ARP180102940A 2017-10-11 2018-10-11 Tratamiento de glomeruloesclerosis focal y segmentaria con antagonistas de ccr2 AR113440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762570778P 2017-10-11 2017-10-11

Publications (1)

Publication Number Publication Date
AR113440A1 true AR113440A1 (es) 2020-05-06

Family

ID=66101688

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102940A AR113440A1 (es) 2017-10-11 2018-10-11 Tratamiento de glomeruloesclerosis focal y segmentaria con antagonistas de ccr2

Country Status (17)

Country Link
US (3) US10758540B2 (es)
EP (1) EP3694504A4 (es)
JP (1) JP2020536919A (es)
KR (1) KR20200070299A (es)
CN (1) CN111417389A (es)
AR (1) AR113440A1 (es)
AU (1) AU2018347361A1 (es)
BR (1) BR112020007183A2 (es)
CA (1) CA3078809A1 (es)
CL (1) CL2020000974A1 (es)
IL (1) IL273717A (es)
MX (1) MX2020003502A (es)
RU (1) RU2020113612A (es)
SG (1) SG11202002975YA (es)
TW (1) TW201922246A (es)
WO (1) WO2019075086A1 (es)
ZA (1) ZA202002049B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266751B (en) * 2016-11-23 2022-07-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
EP3694504A4 (en) * 2017-10-11 2021-07-14 ChemoCentryx, Inc. TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS
JP2022508648A (ja) 2018-10-05 2022-01-19 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4313024A1 (en) * 2021-03-23 2024-02-07 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2024101440A1 (ja) * 2022-11-11 2024-05-16 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3901855A (en) 1974-08-07 1975-08-26 Us Air Force Preparation of polybenzimidazoles
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4227437A (en) 1977-10-11 1980-10-14 Inloes Thomas L Frequency detecting apparatus
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4403607A (en) 1980-05-09 1983-09-13 The Regents Of The University Of California Compatible internal bone fixation plate
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPS61113060A (ja) 1984-11-08 1986-05-30 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
DE3825041A1 (de) 1988-07-20 1990-02-15 Schering Ag Pyrido(3,2-e)(1,2,4)triazolo(1,5-a)pyrimidin- 2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, pflanzenwachstumsregulierender und fungizider wirkung
DE3924424A1 (de) 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
JPH04364168A (ja) 1990-08-08 1992-12-16 Taisho Pharmaceut Co Ltd スルホンアミドピリジン化合物
DE69129611T2 (de) 1990-08-20 1998-12-17 Eisai Co., Ltd., Tokio/Tokyo Sulfonamid-Derivate
JPH06135934A (ja) 1991-12-27 1994-05-17 Ishihara Sangyo Kaisha Ltd ピリジン誘導体又はその塩を含有するホスホリパーゼ▲ａ２▼阻害剤、抗炎症剤又は抗膵炎剤
JPH06145145A (ja) 1991-12-27 1994-05-24 Ishihara Sangyo Kaisha Ltd アミノトリフルオロメチルピリジン誘導体又はその塩、それらの製造方法及びそれらを含有するホスホリパーゼａ▲２▼阻害剤、抗炎症剤並びに抗膵炎剤
US6159686A (en) 1992-09-14 2000-12-12 Sri International Up-converting reporters for biological and other assays
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
US7888466B2 (en) * 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
DK0896533T3 (da) 1996-02-22 2004-01-26 Tularik Inc Pentafluorbenzensulfonamider og analoger
US5780488A (en) 1996-04-03 1998-07-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2288305T3 (es) 1996-09-10 2008-01-01 Theodor-Kocher Institute Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso.
AR015104A1 (es) 1996-11-13 2001-04-18 Dowelanco Compuestos de n-arilsulfilimina sustituidos, utiles como catalizadores en la preparacion de compuestos de n-arilarilsulfonamida; proceso para preparar dichos compuestos y su uso para catalizar dicha preparacion.
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6380206B1 (en) 1998-11-23 2002-04-30 Cell Pathways, Inc. Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives
JP2000159665A (ja) 1998-11-27 2000-06-13 Nippon Kayaku Co Ltd リウマチの予防または治療剤
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
OA11978A (en) 1999-06-28 2006-04-18 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors.
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001335714A (ja) 2000-03-22 2001-12-04 Fuji Photo Film Co Ltd アゾ色素、その製造方法、インクジェット用インク、インクジェット記録方法
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
JP2004501913A (ja) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
JP3699910B2 (ja) 2000-10-31 2005-09-28 株式会社東芝 データ伝送装置、データ伝送方法及びプログラム
ES2274041T3 (es) 2001-06-07 2007-05-16 Chemocentryx, Inc. Ensayo de migracion celular.
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
JP2003040726A (ja) 2001-07-26 2003-02-13 Daito Kasei Kogyo Kk 化粧料
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
EP1458715B1 (en) 2001-12-18 2005-12-07 AstraZeneca AB Novel compounds
US7119112B2 (en) 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
EP1507756B1 (en) 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
JP4611746B2 (ja) 2002-11-18 2011-01-12 ケモセントリックス， インコーポレイテッド アリールスルホンアミド
US20060111351A1 (en) 2002-11-18 2006-05-25 Solomon Ungashe Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US20070021466A1 (en) 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
WO2004056774A2 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
MXPA05006701A (es) 2002-12-20 2006-03-30 Amgen Inc Moduladores de asma y de inflacion alergica.
WO2004058265A1 (en) 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
WO2004105794A2 (en) 2003-05-29 2004-12-09 Abbott Laboratories Continuous dosing regimen with abt-751
WO2005004810A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
CA2594726C (en) 2005-01-14 2013-03-19 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2007014008A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007014054A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US20070219245A1 (en) 2006-03-14 2007-09-20 Cuifen Hou Method of use for substituted dipiperidine ccr2 antagonists
WO2008008394A1 (en) 2006-07-12 2008-01-17 Transform Pharmaceuticals, Inc. Tizanidine succinate salt forms and methods of making and using the same
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
KR101617050B1 (ko) 2007-07-12 2016-05-02 케모센트릭스, 인크. 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
NO2321351T3 (es) 2008-08-18 2018-03-31
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN102933579B (zh) 2009-12-17 2015-07-15 贝林格尔.英格海姆国际有限公司 新的ccr2受体拮抗剂及其用途
EP2621928A1 (en) * 2010-09-27 2013-08-07 Proximagen Limited 7-hydroxy-pyrazolo[1,5-a]pyrimidine compounds and their use as ccr2 receptor antagonists
CA2821985C (en) 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
EP3065744B1 (en) 2013-11-04 2021-04-21 Noxxon Pharma AG A ccl2 antagonist for use in treating proteinuria
AU2016263579B2 (en) 2015-05-21 2020-12-03 Chemocentryx, Inc. CCR2 modulators
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
IL266751B (en) * 2016-11-23 2022-07-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
EP3694504A4 (en) * 2017-10-11 2021-07-14 ChemoCentryx, Inc. TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS

Also Published As

Publication number Publication date
AU2018347361A1 (en) 2020-04-30
ZA202002049B (en) 2021-10-27
CA3078809A1 (en) 2019-04-18
US20210000834A1 (en) 2021-01-07
US20220296601A1 (en) 2022-09-22
US11382915B2 (en) 2022-07-12
US20190134042A1 (en) 2019-05-09
CL2020000974A1 (es) 2020-08-14
TW201922246A (zh) 2019-06-16
WO2019075086A1 (en) 2019-04-18
BR112020007183A2 (pt) 2020-09-24
JP2020536919A (ja) 2020-12-17
CN111417389A (zh) 2020-07-14
MX2020003502A (es) 2021-09-30
US10758540B2 (en) 2020-09-01
SG11202002975YA (en) 2020-04-29
EP3694504A4 (en) 2021-07-14
KR20200070299A (ko) 2020-06-17
EP3694504A1 (en) 2020-08-19
RU2020113612A3 (es) 2022-04-29
IL273717A (en) 2020-05-31
RU2020113612A (ru) 2021-11-12

Similar Documents

Publication Publication Date Title
AR113440A1 (es) Tratamiento de glomeruloesclerosis focal y segmentaria con antagonistas de ccr2
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
CL2021003306A1 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía. (divisional de solicitud nº 201901293)
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
AR101740A1 (es) Terapia de combinación y composiciones
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
EP4324454A3 (en) Cross-linking agents and associated methods
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
CL2020002165A1 (es) Uso de tradipitant para tratar la cinetosis.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2019000846A1 (es) Proteína terapéutica.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.

Legal Events

Date Code Title Description
FB Suspension of granting procedure